Form 10-Q · Quarterly report
Eli Lilly 10-Q, filed Oct 29, 2026
- Filed
- CIK
- 0000059478
- Accession no.
- 0000059478-26-000108
Summary
Eli Lilly's third-quarter 2026 revenue rose 39% to $24.4 billion and net income rose 16% to $6.45 billion, driven by Mounjaro and Zepbound. The company also said the FDA approved insulin efsitora alfa for type 2 diabetes and orforglipron for obesity, and that Phase 3 trials of retatrutide for obesity and type 2 diabetes met their primary endpoints.
Key points
- Eli Lilly's nine-month 2026 revenue was $67.17 billion, up 46% year over year, and diluted earnings per share were $23.42, up 51%.
- Mounjaro, Zepbound, and Foundayo accounted for 66% of total revenue for the nine months ended September 30, 2026.
- The FDA approved tirzepatide (Mounjaro) to reduce cardiovascular risk in type 2 diabetes.
- Under the Medicare GLP-1 Bridge program, Medicare beneficiaries obtained access to discounted Lilly obesity medicines from July 1, 2026 through December 31, 2027.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion EXECUTIVE OVERVIEW This section provides an overview of our financial results, updates to our clinical development pipeline, and other matters affecting our company and industry. Financial Results The following table summarizes certain financial information: Three Months Ended September 30, Percent Change Nine Months Ended September 30, Percent Change 2026 2025 2026 2025 Revenue $ 24,397 $ 17,601 39 $ 67,170 $ 45,887 46 Net income 6,451 5,583 16 20,942 14,002 50 Earnings per share - diluted 7.22 6.21 16 23.42 15.56 51 Revenue increased for the three and nine months ended September 30, 2026, driven primarily by increased volume, partially offset by lower…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.